BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang RS, Cheng YM, Zeng XX, Kim S, Fu P. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease. Chin Med J (Engl) 2016;129:562-9. [PMID: 26904991 DOI: 10.4103/0366-6999.176987] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Assadi F. Rising serum potassium and creatinine concentrations after prescribing renin-angiotensin-aldosterone system blockade: how much should we worry? World J Pediatr 2021;17:552-4. [PMID: 34476759 DOI: 10.1007/s12519-021-00455-8] [Reference Citation Analysis]
2 Zhang Y, Li X, Sha N, Shu B, Zhao Y, Wang X, Xiao H, Shi Q, Wong M, Wang Y. Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss. Bone 2017;97:222-32. [DOI: 10.1016/j.bone.2017.01.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
3 Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K, Praditpornsilpa K, Eiam-ong S, Susantitaphong P. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. Int Urol Nephrol 2018;50:2261-78. [DOI: 10.1007/s11255-018-1991-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Vejakama P, Ingsathit A, McKay GJ, Maxwell AP, McEvoy M, Attia J, Thakkinstian A. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients. BMC Nephrol 2017;18:342. [PMID: 29187194 DOI: 10.1186/s12882-017-0753-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
5 Oyarzún C, Garrido W, Alarcón S, Yáñez A, Sobrevia L, Quezada C, San Martín R. Adenosine contribution to normal renal physiology and chronic kidney disease. Mol Aspects Med 2017;55:75-89. [PMID: 28109856 DOI: 10.1016/j.mam.2017.01.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
6 Der Mesropian PJ, Shaikh G, Cordero Torres E, Bilal A, Mathew RO. Antihypertensive therapy in nondiabetic chronic kidney disease: a review and update. J Am Soc Hypertens 2018;12:154-81. [PMID: 29396103 DOI: 10.1016/j.jash.2018.01.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zheng Y, Cai GY, He LQ, Lin HL, Cheng XH, Wang NS, Jian GH, Liu XS, Liu YN, Ni ZH, Fang JA, Ding HL, Guo W, He YN, Wang LH, Wang YP, Yang HT, Ye ZM, Yu RH, Zhao LJ, Zhou WH, Li WG, Mao HJ, Zhan YL, Hu Z, Yao C, Wei RB, Chen XM. Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study. Chin Med J (Engl) 2017;130:2402-9. [PMID: 29052559 DOI: 10.4103/0366-6999.216407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]